ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
ImmunityBio, Inc. (NASDAQ: IBRX) announced a $320 million royalty financing and equity investment by Oberland Capital, providing financial resources for commercialization efforts and pipeline expansion. The investment is non-dilutive and includes $200 million funded at closing, with the potential for an additional $100 million contingent upon FDA approval of Anktiva® for the treatment of bladder cancer.
Positive
Up to $320 million royalty financing and equity investment provides significant financial resources for ImmunityBio's commercialization efforts and pipeline expansion
Investment is non-dilutive and includes $200 million funded at closing, with the potential for an additional $100 million contingent upon FDA approval of Anktiva® for the treatment of bladder cancer
The investment demonstrates strong confidence by Oberland Capital in ImmunityBio's future and the potential value of Anktiva in bladder cancer treatment
The strategic financing agreement between ImmunityBio and Oberland Capital is a notable event for stakeholders due to the significant influx of capital with minimal shareholder dilution. The structure of the Revenue Interest Purchase Agreement (RIPA) suggests a strong vote of confidence in ImmunityBio's product pipeline and commercial potential, particularly for Anktiva, which is pending FDA approval. The agreement's tiered royalty payment system, contingent upon regulatory milestones, creates a scenario where the financial burden on ImmunityBio is directly correlated with the product's market success, a common strategy to mitigate investor risk in biopharmaceutical ventures.
The equity investment component, with an initial $10 million and an option for an additional $10 million, alongside the RIPA, provides ImmunityBio with immediate and future capital to fund operations without significantly affecting current investors' holdings. This financing mechanism is often more attractive than traditional equity financing, which could lead to stock dilution and downward pressure on share prices. The subordination agreement with Nant Capital further secures Oberland Capital's investment, indicating a carefully structured deal to balance the interests of various stakeholders.
From a financial perspective, the extension of the maturity dates of existing promissory notes and the option for conversion at a premium price indicate a restructuring of debt that could improve ImmunityBio's balance sheet and financial flexibility. This could be perceived positively by the market, potentially impacting the company's stock valuation favorably.
The impending PDUFA date for ImmunityBio's Anktiva in combination with BCG for NMIBC represents a critical juncture for the company's future. Anktiva's approval could catalyze a shift in the standard of care for BCG-unresponsive non-muscle invasive bladder cancer, a condition with limited treatment options. The investment from Oberland Capital, therefore, underscores the potential market opportunity for novel immunotherapies in oncology, a sector with high unmet medical needs and substantial commercial rewards.
The tiered royalty payments in the RIPA are indicative of a risk-adjusted investment strategy commonly seen in the biopharmaceutical industry, where the investor's return is aligned with the product's commercial performance. This can be a prudent approach in an industry where product uptake and peak sales can be uncertain, even after regulatory approval.
Furthermore, the capital infusion is earmarked for expanding the clinical pipeline into multiple solid tumors, which suggests that ImmunityBio is looking to leverage its immunotherapy platform beyond bladder cancer. The success in diversifying its pipeline could be a significant driver of long-term growth, reinforcing the importance of this investment for the company's strategic direction.
The investment by Oberland Capital in ImmunityBio reflects broader market trends where investors are showing interest in late-stage biopharmaceutical companies with differentiated products. The urological cancer space, where ImmunityBio is focusing its efforts, has been attracting attention due to the growing prevalence of bladder cancer and the demand for innovative treatments. The market potential for Anktiva, if approved, could be substantial given the current gaps in treatment for NMIBC.
The terms of the RIPA suggest a keen awareness of the market risks associated with the commercialization of new therapies. By tying the additional $100 million funding to FDA approval, Oberland Capital has effectively hedged its investment against regulatory risk. This kind of structured financing could become more prevalent as investors seek to balance the high-risk, high-reward nature of biopharmaceutical investments.
Moreover, the extension of the maturity dates for existing promissory notes may signal to the market a strategic maneuver by ImmunityBio to stabilize its financial position and ensure sufficient runway for product development and commercialization efforts. This could have a positive impact on investor sentiment, as it reflects prudent financial management and a commitment to long-term value creation.
01/02/2024 - 06:00 AM
Up to $300 million $20 million
Royalty financing includes $200 million $100 million
Equity investment includes $10 million $10 million
Aggregate of $850 million $320 million $530 million
CULVER CITY, Calif. --(BUSINESS WIRE)--
ImmunityBio, Inc. (NASDAQ: IBRX ), a clinical-stage immunotherapy company (“ImmunityBio” or the “Company”), today announced an up to $320 million $210 million
ImmunityBio’s commercialization efforts are in anticipation of potential U.S. Food and Drug Administration (“FDA”) approval of Anktiva in combination with Bacillus Calmette-Guérin (“BCG”) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”) with carcinoma in situ (CIS) with or without Ta or T1 disease. The Company announced on October 23, 2023 that it had resubmitted its Biologics License Application (“BLA”) to the FDA, and announced on October 26, 2023 that the FDA had set a user fee goal date (PDUFA date) for the BLA resubmission of April 23, 2024. The Company’s pipeline is based on broad immunotherapy and cell therapy platforms that are designed to attack cancer and infectious pathogens by activating both the innate and adaptive branches of the immune system in an orchestrated manner.
“This transaction raises significant capital for the Company to support important growth plans, yet with limited equity dilution and with a cap on total payments tied to the initial investment,” said Richard Adcock, Chief Executive Officer and President of ImmunityBio. “Besides providing a capital source at a key inflection point for ImmunityBio, this investment demonstrates strong confidence by Oberland Capital in our future, and in particular in the potential value of Anktiva in bladder cancer, as well as the direction of our clinical pipeline.”
“We are excited to partner with ImmunityBio on the potential launch of Anktiva in the treatment of bladder cancer,” said Andrew Rubinstein, Managing Partner at Oberland Capital. “This investment aligns with our strategy of investing in near-commercial stage biopharmaceutical companies with highly differentiated products and deep clinical pipelines.”
The investment from Oberland Capital takes the form of a $300 million $200 million $100 million $10 million $10 million
In connection with the RIPA, the Company and Nant Capital entered into amendments to extend the maturity dates of certain existing promissory notes with an aggregate principal amount of approximately $505 million $380 million 75% premium to the closing market price on January 3, 2024. Nant Capital and the RIPA Purchaser Agent also concurrently entered into a Subordination Agreement, pursuant to which the Notes were subordinated to the Company’s obligations to the Purchasers under the RIPA.
Jefferies LLC acted as exclusive financial advisor to the Company on the transaction.
About ImmunityBio
ImmunityBio is a vertically-integrated, clinical-stage biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company’s range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. ImmunityBio is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that ImmunityBio believes sharply reduce or eliminates the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases.
N-803 is investigational. Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.
For more information, please visit https://ir.immunitybio.com
About Oberland Capital
Oberland Capital is a private investment firm formed in 2013 with assets under management of approximately $3.5 billion
For more information, please visit www.oberlandcapital.com or contact Johnna Schifilliti at (212) 257-5850.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the financing transactions described herein and use of proceeds to be received from such financing, the ultimate amount of proceeds expected to be received, the regulatory review process and timing thereof, ImmunityBio’s commercialization strategy for N-803, and ImmunityBio’s pipeline and development of therapeutics for cancers and infectious diseases, among others. While ImmunityBio believes the BLA resubmission addresses the issues identified in the FDA’s complete response letter, there is no guarantee that the FDA will ultimately agree that such issues have been successfully addressed and resolved. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as “anticipates,” “believes,” “continues,” “goal,” “could,” “estimates,” “scheduled,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “indicate,” “projects,” “seeks,” “should,” “will,” “strategy,” and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio’s management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio’s statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) the risks and uncertainties associated with the regulatory review process, (ii) whether or not the FDA will ultimately determine that the BLA resubmission and related actions successfully addresses and resolves the issues identified in the FDA’s complete response letter, (iii) uncertainties regarding the timeline of FDA review of the resubmitted BLA, (iv) any inability to successfully work with the FDA to find a satisfactory solution to address any concerns in a timely manner or at all during the review process for the BLA, including any inability to provide the FDA with data, analysis or other information sufficient to support an approval of the BLA, (v) the ability of ImmunityBio and its third party contract manufacturing organizations to adequately address the issues raised in the CRL, (vi) any potential facility re-inspections that may be required regarding ImmunityBio’s third party contract manufacturing organizations or otherwise and results therefrom, (vii) whether the FDA accepts the data and results as included in the BLA resubmission at levels consistent with the published results, or at all, (viii) whether the FDA approval milestone necessary to achieve the second payment of $100 million U.S. Securities and Exchange Commission (“SEC”) on March 1, 2023 and the Company’s Form 10-Q filed with the SEC on November 9, 2023, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC’s website at www.sec.gov . ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240102781220/en/
Investors
Hemanth Ramaprakash, PhD, MBA
ImmunityBio, Inc.
Hemanth.Ramaprakash@ImmunityBio.com
Media
Greg Tenor
Salutem
Gregory.Tenor@Salutem.com
Source: ImmunityBio, Inc.
What is the recent announcement by ImmunityBio, Inc. (NASDAQ: IBRX)?
ImmunityBio, Inc. (NASDAQ: IBRX) announced a $320 million royalty financing and equity investment by Oberland Capital, providing financial resources for commercialization efforts and pipeline expansion.
How much of the investment was funded at closing?
The investment includes $200 million funded at closing, with the potential for an additional $100 million contingent upon FDA approval of Anktiva® for the treatment of bladder cancer.
What does the investment from Oberland Capital demonstrate?
The investment demonstrates strong confidence by Oberland Capital in ImmunityBio's future and the potential value of Anktiva in bladder cancer treatment.
What is the potential use of the proceeds from the investment?
The proceeds will be used to accelerate commercialization efforts, expand the pipeline within the urological cancer space, and fund ongoing business operations and clinical trials expanding N-803 (Anktiva®) indications into multiple solid tumors.
